{"id":"W2159205789","doi":"10.1016/s0140-6736(06)69705-5","title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","year":2006,"lang":"en","type":"review","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":3875,"is_retracted":false,"has_abstract":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"Deutsche Diabetes Gesellschaft; Canada Research Chairs; Juvenile Diabetes Research Foundation Canada; Canadian Diabetes Association; Deutsche Forschungsgemeinschaft; Eli Lilly and Company","keywords":"Vildagliptin; Incretin; Exenatide; Liraglutide; Sitagliptin; Medicine; Type 2 diabetes; Internal medicine; Endocrinology; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Pharmacology; Glucagon-like peptide 1 receptor; Gastric emptying; Diabetes mellitus; Receptor; Agonist","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007282606,0.001269188,0.002572831,0.00241185,0.0002604741,0.001223136,0.001026499,0.001538148,0.004384114],"category_scores_gemma":[0.0009338782,0.000311833,0.0006551326,0.003093135,0.0003741846,0.001531089,0.0007036495,0.002081514,0.002047604],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007188219,"about_ca_system_score_gemma":0.001084684,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001923837,"about_ca_topic_score_gemma":0.005150763,"domain_scores_codex":[0.9997581,0.00004471518,0.00003131635,0.00002929396,0.0001116541,0.00002490175],"domain_scores_gemma":[0.9996166,0.0001545519,0.00009680902,0.000007304236,0.00007949764,0.00004522447],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002450758,0.00008669063,0.0001209593,0.02548467,0.0002633166,0.0003011458,0.00003278168,0.0003572592,0.001064806,0.001292455,0.09748406,0.8732667],"study_design_scores_gemma":[0.0002395236,0.0001911137,0.001211426,0.00896247,0.0005840523,0.001510215,0.00007653583,0.0001414586,0.0002158662,0.002175873,0.9846649,0.00002673036],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004775959,0.998813,0.00005023343,0.0002626893,0.0004119974,0.000003842368,0.00001129037,0.000004624409,0.0003945895],"genre_scores_gemma":[0.000424187,0.9980032,0.0001609085,0.0004048882,0.0004546325,0.000006413578,0.00002468128,0.000001170012,0.0005199246],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004384114,"threshold_uncertainty_score":0.01466626,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02699947715974299,"score_gpt":0.2865942634395749,"score_spread":0.259594786279832,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}